Ulipristal Acetate: A Review in Uterine Fibroids

Karly Garnock-Jones
Compliance with Ethical Standards Funding: The preparation of this review was not supported by any external funding. Conflicts of interest: Karly P. Garnock-Jones is a salaried employee of Adis/Springer, is responsible for the article content and declares no relevant conflicts of interest. Additional information about this Adis Drug Review can be found here. Abstract Oral ulipristal acetate (Esmya®; Fibristal®), a synthetic selective progesterone receptor modulator, is the first selective progesterone modulator to be approved for...
This data repository is not currently reporting usage information. For information on how your repository can submit usage information, please see our documentation.